[Concurrent] Chen Shifei, Deputy Director of the State Drug Administration
Report the good news that everyone is looking forward to. The State Food and Drug Administration has already approved the registration application of the new coronavirus inactivated vaccine of Sinopharm, China Bio-Beijing Company on December 30, that is, last night.
[Explanation] On December 31st, at the press conference of the Joint Prevention and Control Mechanism of the State Council, Chen Shifei, deputy director of the State Drug Administration, first announced the news to the reporters at the conference.
Chen Shifei said that after a series of rigorous review, review, verification, inspection and data analysis, it is concluded that the known and potential benefits of the new coronavirus inactivated vaccine of Sinopharm Zhongsheng Beijing Company outweigh the known and potential risks. Fully meet the preset conditional listing standard requirements.
[Concurrent] Chen Shifei, Deputy Director of the State Drug Administration
So far, 14 vaccines have been approved to enter clinical trials, and 5 of them are undergoing phase III clinical trials, including the newly-announced new coronavirus inactivated vaccine of Sinopharm, China Biotech Beijing, and a batch of vaccines in the preclinical research stage. Drugs are accelerating.
[Explanation] Recently, the topic of the price of the new coronary pneumonia vaccine has attracted widespread public attention.
In response to this, Zeng Yixin, deputy director of the National Health Commission and head of the vaccine research and development team of the Joint Prevention and Control Mechanism of the State Council, responded that vaccines are public products and providing free access to all people is a major prerequisite.
[Concurrent] Zeng Yixin, Deputy Director of the National Health Commission and Head of the Vaccine R&D Team of the Joint Prevention and Control Mechanism Research Team of the State Council
The basic definition and basic attributes of a vaccine are still a public product, and the price may vary according to the scale of use.
But a major premise must be provided free of charge to all people. This is a major premise.
[Concurrent] Zheng Zhongwei, Head of the Vaccine R&D Working Group of the Joint Prevention and Control Mechanism Research Group of the State Council
We will carry out the first step of vaccination for high-risk groups and key groups, the second step for high-risk groups, and the third step for the entire population.
With this push away, the cost will be greatly reduced.
In any case, we firmly believe that the price of the new coronavirus vaccine must be within the acceptable range of ordinary people.
[Explanation] Zeng Yixin introduced that with the approval of vaccines for the conditional listing, especially with the gradual improvement of production and supply guarantee capacity, China will comprehensively and orderly promote the vaccination of the elderly and high-risk groups with underlying diseases, and follow-up to other general populations Inoculation.
[Concurrent] Zeng Yixin, Deputy Director of the National Health Commission and Head of the Vaccine R&D Team of the Joint Prevention and Control Mechanism Research Team of the State Council
At present, my country’s immunization planning expert advisory committee has formulated a unified vaccination plan. We will carry out vaccination in an orderly manner, so that all eligible people can achieve “sufficiency” and gradually build an immune barrier for the entire population to block The spread of the new crown virus has enabled the new crown pneumonia epidemic to be completely controlled.
Reporter Xu Pengpeng reports from Beijing
Editor in charge: [Li Ji]